| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| fentanyl | Drug delivery system, transdermal | 4.2 mg | Discontinued | Unavailable | Manufacturing | 26/09/2025 |
| fentanyl | Drug delivery system, transdermal | 8.4 mg | Discontinued | Unavailable | Manufacturing | 26/09/2025 |
| fentanyl | Drug delivery system, transdermal | 12.6 mg | Discontinued | Unavailable | Manufacturing | 26/09/2025 |
| fentanyl | Drug delivery system, transdermal | 16.8 mg | Discontinued | Unavailable | Manufacturing | 26/09/2025 |
| fentanyl | Drug delivery system, transdermal | 2.1 mg | Discontinued | Unavailable | Manufacturing | 26/09/2025 |
| stannous chloride~etifenin | Injection, powder for | .42 mg~20 mg | Current | Unavailable | Manufacturing | 26/09/2025 |
| nortriptyline | Tablet, film coated | 10 mg | Resolved | Available | Manufacturing | 26/09/2025 |
| ceftazidime pentahydrate | Injection, powder for | 2.328 g | Current | Limited Availability | Manufacturing | 26/09/2025 |
| finasteride | Tablet, film coated | 1 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 26/09/2025 |
| olanzapine | Tablet, orally disintegrating | 5 mg | Anticipated | Available | Manufacturing | 26/09/2025 |
| fentanyl | Drug delivery system, transdermal | 5.1 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 26/09/2025 |
| fentanyl | Drug delivery system, transdermal | 2.55 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 26/09/2025 |
| vecuronium bromide | Injection, powder for | 10 mg | Current | Limited Availability | Manufacturing | 26/09/2025 |
| pioglitazone hydrochloride | Tablet | 49.9 mg | Anticipated | Available | Manufacturing | 26/09/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Manufacturing | 26/09/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Manufacturing | 26/09/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Anticipated | Available | Manufacturing | 26/09/2025 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 4.986 mg | Anticipated | Available | Manufacturing | 26/09/2025 |
| galantamine hydrobromide | Capsule, modified release | 10.252 mg | Current | Unavailable | Manufacturing | 26/09/2025 |
| galantamine hydrobromide | Capsule, modified release | 30.756 mg | Current | Unavailable | Manufacturing | 26/09/2025 |
| galantamine hydrobromide | Capsule, modified release | 20.504 mg | Current | Unavailable | Manufacturing | 26/09/2025 |
| sildenafil citrate | Tablet, film coated | 28.1 mg | Current | Unavailable | Manufacturing | 26/09/2025 |
| quetiapine fumarate | Tablet, modified release | 57.565 mg | Anticipated | Available | Manufacturing | 26/09/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, modified release | .375 mg | Current | Limited Availability | Manufacturing | 26/09/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Unexpected increase in consumer demand | 26/09/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Anticipated | Available | Manufacturing | 26/09/2025 |
| citalopram hydrobromide | Tablet, film coated | 12.495 mg | Current | Unavailable | Manufacturing | 26/09/2025 |
| citalopram hydrobromide | Tablet, film coated | 49.98 mg | Current | Unavailable | Manufacturing | 26/09/2025 |
| fluticasone propionate | Inhalation, powder for | 20 mg/g | Resolved | Available | Manufacturing | 26/09/2025 |
| cidofovir | Injection, concentrated | 75 mg/mL | Resolved | Available | Manufacturing | 26/09/2025 |
| ambrisentan | Tablet, film coated | 5 mg | Anticipated | Available | Manufacturing | 26/09/2025 |
| lorazepam | Tablet | 1 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 26/09/2025 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~41.6 mg | Resolved | Available | Manufacturing | 26/09/2025 |
| stannous chloride dihydrate | Injection, powder for | 19.2 microgram/mL | Current | Unavailable | Manufacturing | 26/09/2025 |
| nizatidine | Capsule, hard | 300 mg | Anticipated | Available | Manufacturing | 26/09/2025 |
| mesalazine | Suppository, compressed | 1000 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 26/09/2025 |
| lidocaine hydrochloride~adrenaline (epinephrine) acid tartrate | Injection, solution | 20 mg/mL~9.1 microgram/mL | Current | Limited Availability | Manufacturing | 25/09/2025 |
| sildenafil citrate | Tablet, uncoated | 35.1 mg | Anticipated | Available | Manufacturing | 25/09/2025 |
| valaciclovir hydrochloride | Tablet, film coated | 556.275 mg | Anticipated | Available | Manufacturing | 25/09/2025 |
| risperidone | Tablet, film coated | 2 mg | Anticipated | Available | Manufacturing | 25/09/2025 |
| bisoprolol fumarate | Tablet | 2.5 mg | Current | Limited Availability | Manufacturing | 25/09/2025 |
| bisoprolol fumarate | Tablet | 5 mg | Anticipated | Available | Manufacturing | 25/09/2025 |
| bisoprolol fumarate | Tablet | 10 mg | Anticipated | Available | Manufacturing | 25/09/2025 |
| sildenafil citrate | Tablet, film coated | 140.45 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 25/09/2025 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 9.972 mg | Current | Limited Availability | Manufacturing | 25/09/2025 |
| exemestane | Tablet, sugar coated | 25 mg | Anticipated | Available | Manufacturing | 25/09/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Resolved | Available | Unexpected increase in consumer demand | 25/09/2025 |
| linezolid | Tablet, film coated | 600 mg | Current | Unavailable | Manufacturing | 25/09/2025 |
| carbidopa monohydrate~entacapone~levodopa | Tablet, film coated | 27 mg~200 mg~100 mg | Current | Limited Availability | Unexpected increase in consumer demand | 25/09/2025 |
| carbidopa monohydrate~entacapone~levodopa | Tablet, film coated | 40.5 mg~200 mg~150 mg | Current | Limited Availability | Unexpected increase in consumer demand | 25/09/2025 |
| levodopa~carbidopa monohydrate~entacapone | Tablet, film coated | 200 mg~54.1 mg~200 mg | Current | Limited Availability | Unexpected increase in consumer demand | 25/09/2025 |
| irbesartan | Tablet, film coated | 150 mg | Current | Unavailable | Manufacturing | 25/09/2025 |
| nizatidine | Capsule, hard | 150 mg | Current | Unavailable | Manufacturing | 25/09/2025 |
| nitisinone | Tablet | 10 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 25/09/2025 |
| nitisinone | Tablet | 5 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 25/09/2025 |
| lamotrigine | Tablet, chewable | 50 mg | Anticipated | Available | Manufacturing | 25/09/2025 |
| lamotrigine | Tablet, chewable | 100 mg | Current | Limited Availability | Manufacturing | 25/09/2025 |
| naltrexone hydrochloride | Tablet, film coated | 50 mg | Resolved | Available | Manufacturing | 25/09/2025 |
| desvenlafaxine | Tablet, modified release | 100 mg | Resolved | Available | Manufacturing | 25/09/2025 |
| valaciclovir hydrochloride | Tablet, film coated | 1112 mg | Anticipated | Available | Manufacturing | 25/09/2025 |
| methyl aminolevulinate hydrochloride | Cream | 200 mg/g | Resolved | Available | Manufacturing | 25/09/2025 |
| terbinafine hydrochloride | Tablet, uncoated | 281.25 mg | Current | Limited Availability | Manufacturing | 24/09/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.9 mg | Current | Limited Availability | Unexpected increase in consumer demand | 24/09/2025 |
| indapamide hemihydrate~perindopril erbumine | Tablet | 1.25 mg~4 mg | Current | Unavailable | Manufacturing | 24/09/2025 |
| tobramycin | Capsule, hard | 28 mg | Anticipated | Available | Manufacturing | 24/09/2025 |
| valsartan~hydrochlorothiazide | Tablet, film coated | 320 mg~25 mg | Current | Unavailable | Manufacturing | 24/09/2025 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~41.583 mg | Resolved | Available | Manufacturing | 24/09/2025 |
| entecavir | Tablet, film coated | 1 mg | Anticipated | Available | Manufacturing | 24/09/2025 |
| anastrozole | Tablet, film coated | 1 mg | Current | Limited Availability | Manufacturing | 24/09/2025 |
| carbidopa monohydrate~levodopa | Tablet, uncoated | 27 mg~100 mg | Current | Limited Availability | Manufacturing | 24/09/2025 |
| cabazitaxel | Injection, concentrated | 60 mg | Current | Limited Availability | Manufacturing | 24/09/2025 |
| oxaliplatin | Injection, concentrated | 100 mg | Resolved | Available | Manufacturing | 24/09/2025 |
| sugammadex sodium | Injection, solution | 217.6 mg | Current | Unavailable | Manufacturing | 24/09/2025 |
| trandolapril | Capsule, hard | 2 mg | Current | Unavailable | Manufacturing | 24/09/2025 |
| Tiger snake antivenom | Injection, concentrated | 3000 U | Resolved | Available | Manufacturing | 24/09/2025 |
| fluvastatin sodium | Tablet, modified release | 84.24 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/09/2025 |
| prazosin hydrochloride | Tablet, uncoated | 2.19 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 23/09/2025 |
| bromocriptine mesilate | Tablet, uncoated | 2.87 mg | Current | Unavailable | Manufacturing | 23/09/2025 |
| Somatropin | Injection, powder for | 12 mg/mL | Anticipated | Available | Unexpected increase in consumer demand | 23/09/2025 |
| fluticasone propionate~salmeterol xinafoate | Inhalation, pressurised | 125 microgram/actuation~36.3 microgram/actuation | Resolved | Available | Unexpected increase in consumer demand | 23/09/2025 |
| capecitabine | Tablet, film coated | 500 mg | Resolved | Available | Unexpected increase in consumer demand | 23/09/2025 |
| Rabies virus | Injection, powder for | 2.5 IU | Current | Limited Availability | Unexpected increase in consumer demand | 23/09/2025 |
| letrozole | Tablet, film coated | 2.5 mg | Current | Limited Availability | Manufacturing | 23/09/2025 |
| posaconazole | Tablet, modified release | 100 mg | Current | Unavailable | Manufacturing | 23/09/2025 |
| Adalimumab | Injection, solution | 20 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 23/09/2025 |
| Adalimumab | Injection, solution | 40 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 23/09/2025 |
| metronidazole | Tablet, film coated | 400 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 23/09/2025 |
| carbidopa monohydrate~levodopa | Tablet, uncoated | 26.9 mg~100 mg | Current | Limited Availability | Manufacturing | 23/09/2025 |
| spironolactone | Tablet, film coated | 100 mg | Current | Limited Availability | Manufacturing | 23/09/2025 |
| bupivacaine hydrochloride monohydrate | Injection, solution | 52.7 mg | Resolved | Available | Manufacturing | 22/09/2025 |
| sertraline hydrochloride | Tablet, film coated | 56 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 22/09/2025 |
| sertraline hydrochloride | Tablet, film coated | 112 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 22/09/2025 |
| varenicline tartrate~varenicline tartrate | Tablet, film coated | 1.71 mg~.85 mg | Discontinued | Unavailable | Manufacturing | 22/09/2025 |
| varenicline tartrate | Tablet, film coated | 1.71 mg | Discontinued | Unavailable | Manufacturing | 22/09/2025 |
| fludarabine phosphate | Injection, powder for | 50 mg | Current | Limited Availability | Manufacturing | 22/09/2025 |
| aripiprazole | Tablet, uncoated | 30 mg | Resolved | Available | Manufacturing | 22/09/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 10 mg | Current | Limited Availability | Manufacturing | 22/09/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.9 mg | Resolved | Available | Unexpected increase in consumer demand | 22/09/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.76 mg | Anticipated | Available | Manufacturing | 22/09/2025 |
| ropivacaine hydrochloride | Injection, solution | 2 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 22/09/2025 |
| ropivacaine hydrochloride | Injection, solution | 7.5 mg/mL | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 22/09/2025 |
| ropivacaine hydrochloride | Injection, solution | 100 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 22/09/2025 |
| quetiapine fumarate | Tablet, modified release | 345.39 mg | Current | Limited Availability | Manufacturing | 22/09/2025 |
| quetiapine fumarate | Tablet, modified release | 345.39 mg | Anticipated | Available | Manufacturing | 22/09/2025 |
| quetiapine fumarate | Tablet, modified release | 230.26 mg | Anticipated | Available | Manufacturing | 22/09/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Unexpected increase in consumer demand | 22/09/2025 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Limited Availability | Manufacturing | 22/09/2025 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Current | Unavailable | Unexpected increase in consumer demand | 22/09/2025 |
| solifenacin succinate | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 22/09/2025 |
| Mecasermin | Injection, solution | 10 mg/mL | Anticipated | Available | Unexpected increase in consumer demand | 22/09/2025 |
| naloxone hydrochloride dihydrate | Injection | 440 microgram | Resolved | Available | Unexpected increase in consumer demand | 22/09/2025 |
| midazolam maleate | Solution | 10.2 mg | Resolved | Available | Manufacturing | 22/09/2025 |
| nitrofurantoin | Capsule, hard | 100 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 22/09/2025 |
| palonosetron hydrochloride~fosnetupitant chloride hydrochloride | Injection, concentrated | 280 microgram~260 mg | Anticipated | Available | Manufacturing | 22/09/2025 |
| thiotepa | Injection, powder for | 15 mg | Current | Unavailable | Commercial Changes / Commercial viability | 22/09/2025 |
| thiotepa | Injection, powder for | 100 mg | Current | Unavailable | Commercial Changes / Commercial viability | 22/09/2025 |
| thiotepa | Injection, powder for | 400 mg | Current | Unavailable | Commercial Changes / Commercial viability | 22/09/2025 |
| nitrofurantoin | Capsule, hard | 100 mg | Current | Limited Availability | Manufacturing | 22/09/2025 |
| clindamycin phosphate | Cream | 22.8 mg/g | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 22/09/2025 |
| midazolam | Injection, solution | 1 mg/mL | Current | Unavailable | Manufacturing | 22/09/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 20 mg | Current | Limited Availability | Manufacturing | 22/09/2025 |
| galantamine hydrobromide~galantamine | Capsule, modified release | 20.51 mg~16 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 22/09/2025 |
2025年9月28日